Replies to post #688025 on NorthWest Biotherapeutics Inc (NWBO)

[User-840664]

Um, the 10K shows total 2023 revenues of $1.92 Million, and that is after 10 years of C Care... WTH are you even talking about?
Nobody wants it and it is likely not getting any approvals...

IMO

[bas2020]

Not moss.... STEAM!

[manibiotech]

Sure
It won’t be anywhere close to 12k every year in UK as stated in the post I was responding to . And that post was was specific for cases in UK
Please reread

[FeMike]

let’s not forget any other soul out there in the world who sees an approval for this and wants to fly to the UK for treatment.

I mean...you can pretty much forget them. Those numbers will be negligible. There's just not that many people that can afford to pay this cost out of pocket.

[Chiugray]

Beachhyena,
Exactly. There may be 12K brain tumor patients, but that is only a segment, ie only newly diagnosed brain tumor patients in the UK per year. If USA stats are proportional, there is a 10.6X ratio of patients living with brain tumor to the newly diagnosed per year number. With DCVax-L approval being a watershed moment, the main goal of every patient with a brain tumor will be to try and get treatment.

My speculation of DCVax-L price in the UK is $200K (between $150K to $300K). If there is a pay by injection sales model to accommodate prophylactic use for lesser stage brain tumors and to make this more practical and affordable for insurance purposes, the fully extrapolated price would be closer to $300K.

Once UK is approved, the odds for approval by Canada, USA, Germany/EU/EMA, and ultimately globally, should increase near 99%. My thinking is the early year(s) valuation multiple of sales should also be much higher (to also reflect the unicorn company growth potential), maybe 12 initially.

The USA brain tumor realizable market is over 7X larger than the UK one. With Germany/EU/EMA and Canada, NWBO is amazingly for a small biotech already global. I would think the rest of the world would quickly open up their insurance and markets as well.